While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view towards winning fast-track status from a European health regulator. The European Medicines Agency (EMA) – “a decentralised agency of the European Union responsible for … safety monitoring,” according to its website – has delivered to Neurizon “notice of a positive opinion” That opinion relates to Neurizon’s bid to acquire Orphan Medicinal Product Designation (OMPD) from EMA for its drug NUZ-001, designed in the hopes it can treat Amyotrophic Lateral Sclerosis (ALS). According …